Pharvaris NV (NAS:PHVS)

Pharvaris NV at RBC Capital Markets Global Healthcare Conference Transcript

May 20, 2026 / 03:00PM GMT

Release Date Price: $29.45 (+1.73%)

Transcript

Nevin Varghese

RBC Capital Markets Inc - Equity Analyst

Hi, everybody. Thank you for joining us for this next session. My name is Nevin Varghese. I'm one of the biotech analysts here at RBC Capital Markets, joined on stage by Pharvaris and the head of IR there, Maggie Beller. Maggie, thank you so much for being here with us.

Maggie Beller

Pharvaris NV - Head of Corporate and Investor Relations

Thanks, Nevin. Thanks for having us.

Questions & Answers

Nevin Varghese;Maggie

RBC Capital Markets Inc - Equity Analyst

Of course. So, let's get into it. I think I'd love to start with the recent pivotal data that we saw from the RAPIDe-3 trial of Deucrictibant IR, where we saw significant on-demand efficacy in acute HAE attacks. I'm curious, since the data and as you've been doing more market research, what specific endpoints that you've seen resonating most with clinicians and patients, whether that be the time to symptom relief or tax sobriety reductions or the time to end of progression.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.